Navigation Links
Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Company's Anthrax Therapeutic
Date:9/25/2007

with or without an antibiotic."

Anthim(TM) Background

Anthim is high affinity monoclonal antibody that targets the protective antigen component of anthrax infection, blocking the bacteria's ability to form deadly toxins. It is being developed for prophylaxis and post-exposure treatment of inhalation anthrax. Anthim has been granted Fast Track status and Orphan Drug Designation by the FDA and is being developed under the FDA Animal Rule, a regulatory process specifically designed for the development of medical countermeasures to bioterror threats. In April of 2007, Anthim was selected to R&D Directions' list of "100 Great Investigational Drugs.

About Elusys' Heteropolymer Antibody(TM) Technology

HP Antibodies represent a new approach for the treatment of antibiotic resistant infections distinct from traditional therapies. HP Antibodies utilize natural immune system mechanisms to clear pathogens and provide a means to develop novel drug candidates targeted against bacterial, viral and fungal infections. By targeting a unique immune receptor, HP Antibodies enhance a natural clearance mechanism and direct the rapid removal of pathogens from the circulation to tissue macrophages. Elusys is currently working on novel approaches to the treatment of Staphylococcus and Candida infections using HP antibodies.

About Elusys

Elusys is a privately held biopharmaceutical company focused on the development of antibody-based therapeutics for the treatment of life- threatening infectious disease. Current venture investors include Essex Woodlands Health Ventures LLC, Invesco Private Capital, Crescendo Ventures, MedImmune Ventures and Pfizer. For more information please visit http://www.elusys.com.


'/>"/>
SOURCE Elusys Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pelosi: Bush Veto of Stem Cell Bill Says No to the Hopes of Million of Families Across America
2. Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million Annually
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
5. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
6. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
7. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
8. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
9. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
10. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
11. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 20, 2014 Depomed, Inc. (NASDAQ: ... the Piper Jaffray 26 th Annual Healthcare Conference in ... the Piper Jaffray conference is scheduled for 8:00 am EST (5:00 ... webcast, and the webcast can be accessed via the Investor Relations ... of the webcast will be archived for 30 days on the ...
(Date:11/21/2014)... Nov. 20, 2014 Oxis International, Inc. (OXIS) (OXI.PA) ... election of Anthony J. Cataldo as Chief Executive ... Effective November 19, 2014, Ken Eaton resigned his ... of Directors of Oxis International, Inc. to pursue new opportunities. ... named Chief Executive Officer of Oxis International, Inc. Mr. Cataldo ...
(Date:11/21/2014)... Texas , Nov. 21, 2014  Lexicon Pharmaceuticals, ... pricing of its previously announced underwritten public offering of ... an effective shelf registration statement. The offering will consist ... offering price of $1.005 per share.  Lexicon has also ... to 7,462,687 additional shares of common stock.  All of ...
Breaking Medicine Technology:Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference 2OXIS International, Inc. announces Changes in Management Team 2OXIS International, Inc. announces Changes in Management Team 3Lexicon Announces Pricing Of Common Stock Offering 2Lexicon Announces Pricing Of Common Stock Offering 3
... CPHD ) today announced that Robert Kwiatkowski, ... of Infectious Disease Research and Development, reporting to David ... impressive menu of eleven highly regarded Xpert® tests for ... extend our leadership with next-generation products, including a number ...
... BETHLEHEM, Pa., June 22, 2011 In a ... of diazepam (NRL-1) achieved positive clinical results in ... was designed and manufactured at Particle Sciences.  In ... pharmacokinetic profile comparable to that reported in the ...
Cached Medicine Technology:Cepheid Appoints Vice President of Infectious Disease Research & Development 2Cepheid Appoints Vice President of Infectious Disease Research & Development 3Particle Sciences Develops Proprietary Nasal Delivery Formulation Used in Neurelis' Recently Announced Successful Phase I Pharmacokinetic Study of NRL-01 (intranasal diazepam) 2
(Date:11/23/2014)... 2014 To show thanks to new and ... of white evening dresses for weddings. Customers who ... , iFitDress.com is a distinguished dress manufacturer, and it is ... worldwide customers for a very long time. The CEO of ... customer will be able to buy not only a beautiful ...
(Date:11/23/2014)... AngelWeddingDress.com has recently updated its online store, offering ... “If you are looking for gorgeous beach wedding dresses ... Here you can enjoy 70% off discounts and all ... big marriage ceremony is the most important dream of ... is uppermost priority. Ophelia, one of customers, said, “I ...
(Date:11/23/2014)... The FDA is Watching: , What ... Webinar**, Dec. 11, 2014 ? Any Time at Your ... on promotional activities is no longer limited to magazine ... at websites, Twitter, journal articles, TV appearances, Facebook and ... 11, for On-Demand access to Timothy Ayers and Michelle ...
(Date:11/23/2014)... 2014 BambooFlooringChina.com , the world’s leader ... strand woven bamboo flooring collection. Now, the business is ... company’s CEO, the promotion is valid until Dec. 20, 2014. ... a smooth and dust-free surface, which makes it very easy ... industry, the company wants to make its website the best ...
(Date:11/22/2014)... Sc (PRWEB) November 23, 2014 A ... opened its doors in the downtown Greenville area. Dr. ... Downtown Greenville , decided to open her own clinic ... amazing results with the patients. , AlignLife believes ... proper tools. With a focus on chiropractic care and ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2Health News:Beach Wedding Dresses Added to Outstanding Online Dress Company AngelWeddingDress.com 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5Health News:Click Strand Woven Bamboo Flooring From Famous Bamboo Flooring Company BambooFlooringChina.com 2Health News:AlignLife of Downtown Greenville is Now Open and Accepting New Patients 2
... Aimed for the ... the body, , ... CA (Vocus) July 6, 2009 -- Until now, determining a person’s lead exposure has been ... thanks to LeadConfirm Professional, a new saliva-based lead test that screens for lead ...
... and undernutrition occurs not in conflicts and natural disasters ... article published this week in open access journal ... of year when the previous year,s harvest stocks have ... and is often under recognized. Bapu Vaitla (Tufts ...
... controls whether muscle cells in blood vessels hasten the ... an article published online today in the journal ... Gladstone Institute of Cardiovascular Disease (GICD) in San Francisco, ... at the University of Rochester School of Medicine and ...
... explain results, study says , FRIDAY, July 3 (HealthDay ... better than their counterparts in England on a memory ... of depression and education and the fact that American ... new study suggests. , The test assessed immediate and ...
... ... - 5-11 October. , ... (PRWeb UK) July 3, 2009 -- Companies and organisations throughout the UK are being urged ... Week - 5-11 October., , ,Employers in all sectors, from the largest business to the ...
... that finding will lead to treatments, , FRIDAY, July 3 ... major cellular flaw that may drive the rapid spread of ... often be treated. But most cases are not detected until ... the cancer into remission, the disease often springs back more ...
Cached Medicine News:Health News:LeadConfirm Professional Now Available at Overstock.com--The First Oral Based Lead Test Makes Getting the Lead Out Easier 2Health News:LeadConfirm Professional Now Available at Overstock.com--The First Oral Based Lead Test Makes Getting the Lead Out Easier 3Health News:LeadConfirm Professional Now Available at Overstock.com--The First Oral Based Lead Test Makes Getting the Lead Out Easier 4Health News:Study in Nature: MicroRNAs hold promise for treating diseases in blood vessels 2Health News:Study in Nature: MicroRNAs hold promise for treating diseases in blood vessels 3Health News:Study in Nature: MicroRNAs hold promise for treating diseases in blood vessels 4Health News:On Memory, Older Americans Outsmart the English 2Health News:Businesses Urged to Sign Up and Celebrate Customer Service 2Health News:Cell Pathway May Be Key to Lung Cancer's Spread 2Health News:Cell Pathway May Be Key to Lung Cancer's Spread 3
EPO EIA Human Cytokines 021-SDX021 Erythropoietin Anemia...
Calcitonin EIA Bone and Mineral Metabolism 021-SDX017...
... an enzyme immunoassay (EIA) kit for the ... the subclass of Anti-Neutrophil Cytoplasmic Antibodies (ANCA) ... an aid in the diagnosis of crescentic ... with vasculitic disorders and glomerulonephritis (GN). They ...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-96 Proteinase...
Medicine Products: